Venezuela Medical Device Registration Exemptions: The Use-Based Boundary
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Exemptions from sanitary registration do exist in Venezuela, but the test is based on use rather than on the product. Where a medical device is imported by an institution recognized by MPPS for testing purposes, or is imported at the request of that institution and is not intended for sale, the device may be exempt from registration.
The practical meaning of this is that the same model number can produce opposite conclusions depending on use. A unit imported as a sample for registration testing may be exempt; the same model imported for commercial sale must be registered. Confusing the two leads companies to conclude that because a unit has already cleared customs, the product may be sold — a conclusion that is wrong at the regulatory level and expensive to unwind at the commercial level, because stock is often already allocated to distributors by the time the error surfaces.
The exemption is therefore best understood as a narrow permission attached to a specific consignment and a specific purpose, not as a status that attaches to the product. Nothing about the exemption survives the end of the activity it was granted for.
That distinction explains why exemption questions are almost always answered by reference to documents rather than to the device. A registration certificate is a statement about a product; an exemption is a statement about a transaction. The first can be shown to a distributor, quoted in a tender or used to support pricing. The second can only be shown to a customs officer at the moment of entry, and it says nothing about whether the goods may subsequently be sold, transferred or used outside the purpose for which they were admitted.
2. Legal basis
| Instrument | Reference | Publication date | Provision / point |
|---|---|---|---|
| Circular N° DGSACS-008/2026 | DGSACS-008/2026 | July 9, 2026 | Restatement of the sanitary requirements for import of goods under legal regimes 3 and 12 |
| Decreto N° 4.944 (customs tariff) | G.O. N° 6.804 Extraordinario | April 25, 2024 | Article 37: application of the legal regime column |
| Exception to non-tariff restrictions for samples | USDA GAIN report VE2026-0007 | July 2026 | Samples intended for registration, testing, research, verification or analysis do not fall under non-tariff restrictions where quantity, nature and value do not constitute a commercial purpose |
Basis of the figures: the position that registration may be waived for devices imported by an MPPS-recognized institution for testing or non-sale purposes is a practical estimate widely cited in the industry. The exception to non-tariff restrictions for samples is drawn from the USDA Foreign Agricultural Service GAIN report VE2026-0007 of July 2026; it is a third-party official source, not Venezuelan domestic legislation.
3. Expert insights
Insight 1: the exemption has three constituent elements, and all three are required. The subject element is an institution recognized by MPPS. The act element is importation for testing, or importation at the request of that institution. The purpose element is the absence of a sales purpose. In practice the purpose element is where files fail, because whether something is intended for sale is a matter of intent and intent has to be supported by objective evidence — purchase orders, pricing records, allocation lists, marketing material. A declaration of non-commercial purpose that is contradicted by any of these documents is worse than no declaration at all.
Insight 2: sample treatment and registration exemption are concepts at two different levels. Samples benefit from an exception to non-tariff restrictions, which operates at the customs clearance level. Registration exemption is a waiver of the market access obligation, which operates at the regulatory level. A sample may enjoy clearance facilitation and still require registration, and the reverse is equally possible. Companies routinely conflate the two, usually because the same word — sample — is used in both contexts, and the consequence is a plan that treats a customs outcome as a regulatory one.
Insight 3: the burden of proof rests with the importer. The importer must demonstrate that quantity, nature and value do not amount to a commercial purpose. That requires a complete evidentiary chain linking the import documents, the internal allocation records and the testing commission agreement. If any link is missing, the exemption can be denied retroactively, and responsibility follows the consignment back to the importer of record rather than to the manufacturer who shipped it.
A useful discipline is to define the number of units before the consignment is built, derived from the test protocol rather than from available stock. Quantity is the element most easily documented and the one most often inflated for convenience, which is precisely why it attracts scrutiny.
A fourth observation concerns timing rather than substance. Exemptions are examined at the moment of import and again, potentially, at the moment of any later audit or enforcement action. That means the evidence file supporting a consignment must remain retrievable for years after the goods have been consumed in testing. Many companies keep the documents only until clearance is complete, which is exactly the point from which their value as a defence begins.
4. Practical recommendations
- Confirm in writing, before import, how the consignment is characterized, and obtain the commissioning or request document issued by the MPPS-recognized institution.
- Keep quantities proportionate to the testing requirement and avoid importing in batches that exceed a reasonable testing quantity, even where the surplus would be convenient to hold locally.
- Preserve the full evidentiary chain: the testing commission agreement, the sample list, the internal allocation records and the test result reports.
- Set an internal rule that samples imported under exemption must not enter commercial channels, and mark the physical units so that the distinction is visible in a warehouse inspection rather than only in the file.
5. Verification checklist
- □ The commissioning or request document from the MPPS-recognized institution has been obtained
- □ Import quantities are proportionate to the testing requirement and show no commercial-scale characteristics
- □ All four elements of the evidentiary chain are complete: commission agreement, sample list, allocation records, test reports
- □ An internal control rule prohibits commercial sale of exempt samples
- □ The correct declaration category for this import on the COMEX platform has been confirmed
Regulatory information verified as of October 29, 2026.
GRZAN provides registration support in Venezuela for manufacturers, importers and authorized representatives, including the characterization of sample consignments, exemption documentation and coordination with recognized institutions. For scope and document requirements, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us